ascopubs.org

Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting ...
Nasdaq

Kite Reports Primary Overall Survival Analysis Results Of Phase 3 ZUMA-7 Study

(RTTNews) - Kite, a Gilead Company (GILD), announced the primary overall survival analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta ...
Foreign Policy

South Africa Should Take Zuma’s Threats Seriously

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...
The Africa Report

Why is Jacob Zuma making threats against the ANC?

Former president Jacob Zuma’s lawyers have sent a letter to the African National Congress (ANC) demanding that his membership be reinstated by the end of the month. If this demand is not met, “he may ...
ascopubs.org

Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second ...

Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. In-field recurrences in relapsed/refractory (R/R) ...